Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Qbiotix Limited has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to CASH, KAILEY ELIZABETH, who is the busiest examiner for the company. The portfolio is currently limited to 1 distinct examiner and a single distinct art unit.
This indicates a highly focused approach to its active US patent prosecution. With only 1 pending office action, the company's immediate progress in the biotech sector depends on the interaction with CASH, KAILEY ELIZABETH. The concentration in one art unit suggests a specialized technical focus that has not yet branched into broader pharmaceutical disciplines.
Practitioners should analyze the examiner's historical allowance rates to better predict the timeline for this case. Because the entire active workload resides with an individual official, the company's patent strategy is sensitive to that person's specific requirements. Future expansion may require navigating additional art units as the company broadens its biotech filing strategy.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CASH, KAILEY ELIZABETH | 1 | 28.6% | +64.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18262331 | TARGET-DEPENDENT POLYMERISATION OF OLIGONUCLEOTIDES | CASH, KAILEY ELIZABETH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18262331 | TARGET-DEPENDENT POLYMERISATION OF OLIGONUCLEOTIDES | CASH, KAILEY ELIZABETH | — |
| Art Unit | Apps |
|---|---|
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18262331 | TARGET-DEPENDENT POLYMERISATION OF OLIGONUCLEOTIDES | CASH, KAILEY ELIZABETH | 1683 | §102§103§112 | Non-Final OA | — | Pending | Jul 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialQbiotix Limited has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Kailey Elizabeth Cash has the most, with 1 of Qbiotix Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.